Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

NCT04636008 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Anti-PD-1 Antibody
Radiotherapy
Rectal Cancer
MSI-H
Mmr Deficiency

Interventions

DRUG: Sintilimab
RADIATION: Hypofractionated Radiotherapy

Sponsor

West China Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]